SCHEMBL18323504

SCHEMBL18323504

CSc1cc(NC(=O)c2cc(Br)c(S(N)(=O)=O)cn2)cs1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.34
▸ CA2 P00918 3/20 0.34
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ BACE1 P56817 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ GRM4 Q14833 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ APP P05067 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CA9 Q16790 3/20 0.32
▸ CA12 O43570 2/20 0.32
▸ EGFR P00533 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18323294 0.73 NPC1 (0.49) CA1CA2MEN1KMT2ARAB9A
SCHEMBL18323503 0.73 ALDH1A1 (0.49) CA1CA2MEN1KMT2ALMNA
SCHEMBL18323502 0.68 SCN10A (0.49) RAB9AMAPTNPC1SMN1; SMN2
SCHEMBL18323181 0.67 ATR (0.37) CA1CA2MEN1KMT2ALMNA
SCHEMBL18323170 0.61 THRB (0.34) KMT2ALMNARAB9AGRM4MAPT
SCHEMBL15907179 0.58 RAB9A (0.52) MEN1KMT2ALMNARAB9AMAPT
SCHEMBL18323129 0.58 F10 (0.45) CA2MEN1KMT2ARAB9ANPC1
SCHEMBL231811 0.57 ALDH1A1 (0.54) MEN1KMT2ABACE1LMNARAB9A
SCHEMBL232185 0.57 GRM5 (0.49) MEN1KMT2ARAB9AGRM4MAPT
SCHEMBL15907194 0.55 ALDH1A1 (0.53) MEN1KMT2ALMNARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 — — US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 — — US disclosed
Send feedback